The new neuromuscular blocking agents: Do they offer any advantages?

British Journal of Anaesthesia

Volumn 87, Issue 6, 2001, Pages 912-925

  Moore, E W ^a   Hunter, J M ^a  

^a School of Anaesthesia   (United Kingdom)

Author keywords

Neuromuscu lar block, tropinyl diesters; Neuromuscular block, aminosteroids; Neuromuscular block, benzylisoquinoliniums; Neuromuscular block, tetrahydroisoquinolinium chlorofumarates

Indexed keywords

ACETIC ACID DERIVATIVE; ALFENTANIL; ATRACURIUM; BENZYLISOQUINOLINE DERIVATIVE; BIS TETRAHYDROISOQUINOLINIUM CHLOROFUMARATE; BIS [N [2,6 DICHOROBENZYL]TROPANIUM 3 ALPHA YL]GLUTARATE DIBROMIDE; BROMINE DERIVATIVE; CHOLINESTERASE INHIBITOR; CISATRACURIUM; CYCLODEXTRIN; DOXACURIUM; DRUG METABOLITE; ESTER DERIVATIVE; FENTANYL; G 164; GW 280430A; ISOQUINOLINE DERIVATIVE; LAUDANOSINE; MIVACURIUM; NEOSTIGMINE; NEUROMUSCULAR BLOCKING AGENT; NITROUS OXIDE; ORG 9488; PANCURONIUM; PROPOFOL; RAPACURONIUM BROMIDE; ROCURONIUM; SUXAMETHONIUM; THIOPENTAL; TROPINYL DIESTER DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VECURONIUM;

ANAPHYLAXIS; BRONCHOSPASM; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; KIDNEY DISEASE; LIVER DISEASE; LIVER METABOLISM; NERVE BLOCK; NEUROMUSCULAR BLOCKING; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; REVIEW; VAGUS NERVE;

EID: 0035198976     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/87.6.912     Document Type: Review

References (121)

1. Rapacuronium for modified rapid sequence induction in elective Caesarean section: Neuromuscular blocking effects and safety compared with succinylcholine, and placental transfer
2. The neuromuscular blocking action of ORG NC45, a new pancuronium derivative, in anaesthetized patients: A pilot study
3. Efficacy and safety of divided dose administration of mivacurium for a 90-second tracheal intubation
4. Studies on a new rapid onset and short-acting neuromuscular blocking agent, TAAC3, in anaesthetised cats
5. A large simple randomized trial of rocuronium versus succinylcholine in rapid-sequence induction of anaesthesia along with propofol
6. Anaphylaxis to mivacurium
7. Clinical pharmacology of doxacurium chloride: A new long-acting nondepolarizing muscle relaxant
8. The neuromuscular and cardiovascular profile of GW280430A, a new ultrashort-acting muscle relaxant in cats
9. Dose-response relations of GW280430A in the adductor pollicis under propofol, nitrous oxide, opioid anesthesia
10. Neuromuscular blocking effects of GW280430A at the adductor pollicis and larynx in human volunteers
11. Pharmacology of the novel neuromuscular blocking agent GW280430A in rhesus monkeys: A comparison with mivacurium
12. Disposition of vecuronium bromide in the cat
13. Hepatobiliary disposition of vecuronium bromide in man
14. Muscle relaxants of the future
15. Chemical chelation as a novel method of NMB reversal - Discovery of Org 25969
16. A comparison of the pharmacodynamics of rocuronium and vecuronium during halothane anaesthesia
17. Bis and mixed tetra hydroisoquinolinium chlorofumarates: New ultra-short-acting nondepolarizing neuromuscular blockers
18. Structure-activity relationships of the asymmetrical mixed-onium chlorofumarate neuromuscular blocker GW280430A and some congeners in rhesus monkeys
19. Structure: Action relationships among some desacetoxy analogues of pancuronium and vecuronium in the anesthetized cat
20. Comparison of the pharmacodynamics and the pharmacokinetics of an infusion of cis-atracurium isomer of atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive care unit
21. Pharmacodynamics of the 1R cis- 1′R cis isomer of atracurium (51W89) in health and chronic renal failure
22. Comparison of twitch depression of the adductor pollicis and the respiratory muscles: Pharmacodynamic modeling without plasma concentrations
23. Age related variability in the effects of mivacurium in paediatric surgical patients
24. Cisatracurium besilate: A review of its pharmacology and clinical potential in anaesthetic practice
25. Anaphylactic reaction after cisatracurium
26. Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and in those with hepatic or renal failure
27. Pharmacokinetics of mivacurium in normal patients and in those with hepatic or renal failure
28. Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure
29. Paralysis induced in anaesthetized adult subjects by Org NC 45
30. A comparison of mivacurium infusion requirements between young and elderly adult patients
31. Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end stage liver disease undergoing liver transplantation
32. Org 9487 neuromuscular block at the adductor pollicis and the laryngeal adductor muscles in humans
33. Pharmacodynamics of mivacurium chloride in patients with hepatic cirrhosis
34. Effect of oral antihistamine premedication on mivacurium-induced histamine release and side effects
35. Onset time, endotracheal intubating conditions, and plasma histamine after cisatracurium and vecuronium administration
36. The lack of histamine release with cisatracurium: A double blind comparison with vecuronium
37. Not all muscles are the same
38. Onset of action of relaxants
39. Anaphylaxis to rocuronium
40. Pharmacokinetics, pharmacodynamics, and dose response relationships of pancuronium in control and elderly subjects
41. Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis
42. Pharmacokinetics of 1R-cis 1′R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure
43. Elimination of atracurium in humans: Contribution of Hofmann elimination and ester hydrolysis versus organ-based elimination
44. Effect of renal failure and cirrhosis on the pharmacokinetics and neuromuscular effects of rapacuronium administered by bolus followed by infusion
45. Factors affecting the pharmacokinetic characteristics of rapacuronium
46. Pharmacodynamic modeling of vecuronium-induced twitch depression. Rapid plasma-effect site equilibration explains faster onset at resistant laryngeal muscles than at the adductor pollicis
47. Rapacuronium and bronchospasm
48. Rapacuronium (Org 9487): Do we have a replacement for succinylcholine?
49. A structure-activity study of a series of neuromuscular blocking bis-tropinyl diesters in the rat
50. Neuromuscular blocking N,N'-polymethylene bistropanium, bis 3α-hydroxytropanium and bis 3-oxotropanium compounds
51. Pharmacology of G-1-64, a new non-depolarising neuromuscular blocking agent with rapid onset and short duration of action
52. Comparison of recovery following rapacuronium with and without neostigmine and succinylcholine
53. Pharmacokinetics of the three isomers of mivacurium and pharmacodynamics of the chiral mixture in hepatic cirrhosis
54. Cardiopulmonary effects of the ultrashort neuromuscular blocking drug GW280430A in dogs
55. Pharmacodynamics of the novel neuromuscular blocking drug GW280430A in dogs
56. Comparison of vecuronium, atracurium and tubocurarine in normal patients and in patients with no renal function
57. Use of atracurium during general surgery monitored by the train-of-four stimuli
58. New neuromuscular blocking drugs
59. Rocuronium: The newest aminosteroid neuromuscular blocking drug
60. Data on the distribution of fibre types in thirty-six human muscles: An autopsy study
61. Dose-ranging study in younger adult and elderly patients of Org 9487, a new, rapid-onset, short-duration muscle relaxant
62. 50) and cardiovascular effects of rapacuronium (Org 9487) during narcotic-nitrous oxide-propofol anesthesia in neonates, infants, and children
63. Clinical neuromuscular pharmacology of pancuronium
64. Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis
65. The neuromuscular blocking effects and pharmacokinetics of Org 9426 and Org 9616 in the cat
66. Importance of the organ-independent elimination of cisatracurium
67. Pancuronium, gallamine, and d-tubocurarine compared: Is speed of onset inversely related to drug potency?
68. Severe bronchospasm and desaturation in a child associated with rapacuronium
69. Severe anaphylactic shock after atracurium
70. Epidémiologie des réactions anaphylactoïdes peranesthésiques. Quatriéme enquête multicentrique (juillet 1994-décembre 1996)
71. Anaphylactic reactions to rocuronium
72. 51W89: Dose-response, neuromuscular blocking profile and cardiovascular effects
73. 2-sufentanil anesthesia
74. Weal and flare responses to intradermal rocuronium and cisatracurium in humans
75. The effects of rapacuronium on histamine release and haemodynamics in adult patients undergoing general anesthesia
76. The cardiovascular effects and histamine-releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia
77. Spontaneous and edrophonium augmented recovery from GW280430A-induced neuromuscular block
78. Determination of the cardiovascular effects of GW280430A in anesthetized male volunteers
79. The pharmacodynamics and pharmacokinetics of vecuronium in patients anesthetized with isoflurane with normal renal function or with renal failure
80. Comparison of rocuronium, succinylcholine and vecuronium for rapid sequence induction of anesthesia in adult patients
81. The pharmacokinetic and neuromuscular effects of rocuronium bromide in patients with liver disease
82. Pharmacokinetics and pharmacodynamics of rocuronium (Org 9426) in elderly surgical patients
83. Spontaneous or neostigmine-induced recovery after maintenance of neuromuscular block with Org 9487 (rapacuronium) or rocuronium following an initial dose of Org 9487
84. Comparison of rocuronium and suxamethonium for use during rapid sequence induction of anaesthesia
85. Bronchospasm after rapacuronium in infants and children
86. Comparison of intubating conditions of Org 9487 and succinylcholine
87. The comparative potency and pharmacokinetics of pancuronium and its metabolites in anesthetized man
88. Antagonism of rapacuronium using edrophonium or neostigmine: Pharmacodynamics and pharmacokinetics
89. How serious is the bronchospasm induced by rapacuronium?
90. Histamine release and haemodynamic changes produced by rocuronium, vecuronium, mivacurium, atracurium and tubocurarine
91. Histaminoid reactions associated with rocuronium
92. A comparison of cisatracurium (51W89) and atracurium by infusion in critically ill patients
93. Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients
94. Pharmacokinetics of atracurium and laudanosine in patients with hepatic cirrhosis
95. Mivacurium neuromuscular block at the adductor muscles of the larynx and adductor pollicis in humans
96. Pharmacokinetics and pharmacodynamics of rocuronium at the vocal cords and the adductor pollicis in humans
97. Relationship between chemical structure and physiochemical properties of series of bulky organic cations and their hepatic uptake and biliary excretion rates
98. Early reversal of rapacuronium with neostigmine
99. Rocuronium: High risk for anaphylaxis?
100. Transcutaneous electrical stimulation of the recurrent laryngeal nerve in monkeys
101. Pharmacokinetics and pharmacokinetic-dynamic relationship between rapacuronium (Org 9487) and its 3-desacetyl metabolite (ORG 9488)
102. Comparison of vecuronium with ORG 9487 and their interaction
103. Clearance of atracurium and laudanosine in the urine and by continuous venovenous haemofiltration
104. Changes in plasma catecholamine concentrations and haemodynamic effects of rocuronium and vecuronium in elderly patients
105. Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly patients
106. Comparison of intubating conditions after rapacuronium (Org 9487) and succinylcholine following rapid sequence induction in adult patients
107. Influence of renal failure on the pharmacokinetics and neuromuscular effects of a single dose of rapacuronium bromide
108. Rocuronium in infants, children and adults during balanced anaesthesia
109. Clinical pharmacology of rocuronium (Org 9426): Study of the time course of action, dose requirement, reversibility, and pharmacokinetics
110. Pharmacokinetics and pharmacodynamics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent
111. New fast neuromuscular blocking agent TAAC3 in the anaesthetised monkey
112. New fast neuromuscular blocking agent, TAAC3, in the anaesthetised dog
113. The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis
114. Skin testing and the anaesthetist
115. Comparison of neuromuscular effects, efficacy and safety of rocuronium and atracurium in ambulatory anaesthesia
116. Preliminary investigations of the clinical pharmacology of three short-acting non-depolarising neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487
117. The pharmacodynamics and pharmacokinetics of Org 9426 a new non-depolarising neuromuscular blocking agent in patients anaesthetized with nitrous oxide, halothane and fentanyl
118. Pharmacokinetics and pharmacokinetic/dynamic relationship of rocuronium bromide in humans
119. Time course of action and endotracheal intubating conditions of Org 9487, a new short-acting steroidal muscle relaxant; a comparison with succinylcholine
120. A pharmacodynamic explanation for the rapid onset/offset of rapacuronium bromide
121. Mivacurium chloride: A study to evaluate its use during propofol nitrous oxide anaesthesia